Abstract
Book ReviewsPrognostic and Predictive Value of p53 Mohammed AkhtarMD, FCAP Mohammed Akhtar Head, Division of Anatomic Pathology, Department of Pathology and Laboratory, Medicine (MBC 10), King Faisal Specialist Hospital and Research Centre, P.O. Box 3354 Riyadh 11211, Saudi Arabia Search for more papers by this author Published Online::1 Sep 1998https://doi.org/10.5144/0256-4947.1998.482SectionsPDF ToolsAdd to favoritesDownload citationTrack citations ShareShare onFacebookTwitterLinked InRedditEmail AboutIntroductionThis is the first of a new series of books published under the auspices of the European School of Oncology. As the title indicates, the book deals with the most important gene involved in carcinogenesis, namely, p53. The book consists of 10 articles written by different experts in the field. The first paper, by Thierry Soussi of Institut Curie, Paris, France, entitled "The p53 tumor suppressor gene: From molecular biology to clinical investigation," tries to bring together the current knowledge regarding molecular pathology of p53 and its role in the pathogenesis and management of various human cancers.The next four chapters primarily deal with the role of p53 in breast cancer and discuss such subjects as the role of p53 in the management of breast cancer, the significance of p53 protein accumulation in human breast cancer, the impact of p53 status on breast tumor biology and response to therapy, and the relation of p53 expression to tumor differentiation and endocrine response in breast cancer. An interesting article by G. Gasparini and A.L Harris discusses the relationship between p53 and angiogenesis in neoplasia. Although at present, the relationship between the two is limited and controversial, this appears to be an exciting area for future research. The final paper, by Ingo B. Runnebaum, discusses the role of p53 genotypes and haplotypes in risk assessment in cancer patients and the prospects of retroviral p53 transduction for gene therapy of breast cancer. This is extremely interesting and stimulating work which deals with transduction of wild type p53 in MDAMB231 breast cancer cells.Since 1979, when the p53 gene was first described, thousands of papers have been written underlying the importance of this gene. In 1993, it was declared to be the gene of the year. Since then, a lot has been learned about the clinical implications of p53 as it relates to clinical management and therapy of patients with a variety of cancers, especially breast cancer.The book would definitely appeal to pathologists and oncologists interested in the diagnosis, prognosis and management of cancer, as well as researchers involved in the study of the genesis and progression of cancer. If the first book is any indication, subsequent books published by the European School of Oncology are bound to be equally exciting. Previous article Next article FiguresReferencesRelatedDetails Volume 18, Issue 5September 1998 Metrics History Published online1 September 1998 InformationCopyright © 1998, Annals of Saudi MedicinePDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
